Gene Delivery Technologies Global Market Report 2024

The gene delivery technologies market has grown rapidly in recent years. It will grow from $3.57 billion in 2023 to $4.11 billion in 2024 at a compound annual growth rate (CAGR) of 15.2%. The growth observed in the historic period can be attributed to an improved comprehension of genetic diseases, progress in cell therapy, the development of nanotechnology, the expansion of gene therapy trials, and an increase in research funding.

The gene delivery technologies market is expected to see rapid growth in the next few years. It will grow to $6.96 billion in 2028 at a compound annual growth rate (CAGR) of 14.1%. The anticipated growth in the forecast period can be ascribed to the development of precision medicine, improvements in the regulatory framework, the widespread adoption of gene therapy, and the expansion of non-viral delivery systems. Noteworthy trends expected in the forecast period encompass the application in rare diseases, an increase in clinical trials, the advancement of targeted drug delivery, the expansion of cell therapy, and the development of gene editing tools.

The anticipated growth of the gene delivery technologies market is expected to be propelled by the increasing number of cell and gene therapies. Cell and gene therapies represent medical treatments designed to cure or alleviate diseases by modifying the genetic and cellular makeup of a patient's body. This surge in therapies is driven primarily by advancements in gene editing technologies, playing a crucial role in the development and commercialization of cell and gene therapies. According to an article published by Economist Impact in October 2022, approximately 2,600 clinical trials for CGTs were underway by mid-2021, with researchers estimating 100 approved CGTs in the United States by 2031. The FDA is also projected to approve an average of 8 or 9 CGTs per year between 2022 and 2031, indicating a significant increase in demand for these therapies. Thus, the growing prevalence of cell and gene therapies is a key driver for the gene delivery technologies market.

The rising incidence of genetic disorders is anticipated to contribute to the growth of the gene delivery technologies market. Genetic disorders result from abnormalities in an individual's DNA, affecting the instructions for the development, functioning, and maintenance of the human body. Gene delivery technologies play a crucial role in addressing genetic disorders by introducing functional genes, correcting mutations, and modulating gene expression to provide targeted therapeutic interventions. As reported by Guardian News & Media Limited in August 2022, over 300,000 children worldwide are expected to be born with sickle cell disease in 2022, impacting approximately 5% of the global population. Therefore, the increasing prevalence of genetic disorders is a significant factor driving the growth of the gene delivery technologies market.

Technological advancement has become a prominent trend in the gene delivery technologies market. Major players in the market are directing their efforts toward the development of advanced products to fortify their market positions. For instance, in February 2023, Aera Therapeutics, a US-based biotechnology company, introduced Aera's Platform delivery technology, aiming to unlock the potential of genetic medicines. Aera's PNP technology facilitates precise targeting of RNA molecules implicated in disease processes, enabling the targeted editing of genes in a patient's cells and offering potential for personalized gene therapies.

Leading companies in the gene delivery technologies market are prioritizing technological platforms such as Flowfect Discover's cellular and genome engineering platforms to expedite the development and commercialization of their innovative technologies. Flowfect Discover is a platform revolutionizing cell therapy development by empowering researchers and therapeutic developers to engineer cells with unprecedented precision and efficiency. For example, in May 2021, Kytopen Corp., a US-based biotechnology company, introduced an early access program for its innovative gene delivery platform, Flowfect Discover. This high-throughput gene editing platform utilizes Kytopen's patented electro-mechanical continuous flow technology, featuring attributes such as a closed-system design for enhanced sterility and safety, real-time monitoring and data acquisition for process control, and a user-friendly interface for ease of operation.

In June 2021, PerkinElmer, a US-based company specializing in diagnostics and life sciences, acquired SIRION Biotech for an undisclosed amount. This acquisition aimed to enhance PerkinElmer's capabilities in gene therapy and viral vector technologies, crucial for the development of gene therapies across various diseases. It also bolstered the company's standing as a provider of gene delivery technologies, enabling it to better cater to the growing demand for gene therapies. SIRION Biotech is a German-based provider of viral vector and gene delivery therapy.

Major companies operating in the gene delivery technologies market report are Thermo Fisher Scientific Inc., QIAGEN NV, Horizon Discovery Group Co, OriGene Technologies Inc., Oxford Biomedica Solutions LLC, SignaGen Laboratories LLC, Vectalys SAS, Takara Bio Inc., Bio-Rad Laboratories Inc., System Biosciences LLC, Promega Corporation, Hoffmann-La Roche AG, Catalent Inc., Avantor, Pfizer Inc., Becton Dickinson and Company, Novartis AG, Intellia Therapeutics Inc., Editas Medicine Inc., CRISPR Therapeutics AG, Spark Therapeutics Inc., Bluebird Bio Inc., Sarepta Therapeutics Inc., Regenexxbio Inc., Beam Therapeutics Inc., Verve Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Moderna Inc., BioNTech SE, Translate Bio Inc., CureVac N.V., Lonza Group AG.

North America was the largest region in the gene delivery technologies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global gene delivery technologies market report during the forecast period. The regions covered in the gene delivery technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene delivery technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of gene delivery technologies modes include biological, chemical, and physical approaches. Biological methods involve the use of living organisms or their derivatives in the development and delivery of gene therapy products. Various techniques, such as ex vivo, in vivo, and in vitro applications, are employed in gene therapy, cell therapy, vaccines, and research.

The gene delivery technologies market research report provides gene delivery technologies market statistics, including gene delivery technologies industry global market size, regional shares, competitors with a gene delivery technologies market share, detailed gene delivery technologies market segments, market trends and opportunities, and any further data you may need to thrive in the gene delivery technologies industry. This gene delivery technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gene delivery technologies market consists of revenues earned by entities by providing services such as viral vector production, gene editing, gene therapy, and cell therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Gene delivery technologies also include sales of viral and non-viral vectors, transfection reagents, gene editing tools that are used in providing gene delivery. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.